Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?
作者信息
Dauby Nicolas
机构信息
Department of Infectious Diseases, CHU Saint-Pierre, Brussels, Belgium.
Institute for Medical Immunology, Université Libre de Bruxelles (ULB), Brussels, Belgium.
出版信息
Clin Infect Dis. 2021 Aug 2;73(3):e847-e848. doi: 10.1093/cid/ciaa1600.
Abstract
摘要
相似文献
1
Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?法匹拉韦作为2019冠状病毒病（COVID-19）的抗病毒药物：相同的脚本，不同的演员阵容？
Clin Infect Dis. 2021 Aug 2;73(3):e847-e848. doi: 10.1093/cid/ciaa1600.
2
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).非那韦和对 SARS-CoV-2 感染（COVID-19）早期门诊治疗的需求。
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.02017-20.
3
Comment on: Favipiravir, an antiviral for COVID-19?关于：法匹拉韦，一种用于治疗新冠肺炎的抗病毒药物？的评论
J Antimicrob Chemother. 2021 Jan 1;76(1):279-280. doi: 10.1093/jac/dkaa378.
4
Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.口服法匹拉韦治疗严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒RNA清除延迟患者：病例系列
Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.
5
Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19.法匹拉韦在两名新冠肺炎患者中引起肾毒性。
J Assoc Physicians India. 2021 Jan;69(1):90.
6
Case studies of SARS-CoV-2 treated with favipiravir among patients in critical or severe condition.重症或危重症 SARS-CoV-2 患者使用法匹拉韦治疗的病例研究。
Int J Infect Dis. 2020 Nov;100:283-285. doi: 10.1016/j.ijid.2020.08.047. Epub 2020 Aug 21.
7
Favipiravir Induced Nephrotoxicity in two Patients of COVID-19.法匹拉韦在两名新冠肺炎患者中引起肾毒性。
J Assoc Physicians India. 2021 Jun;69(6):11-12.
8
Outcome of early-stage combination treatment with favipiravir and methylprednisolone for severe COVID-19 pneumonia: A report of 11 cases.早期联合使用法匹拉韦和甲泼尼龙治疗重症 COVID-19 肺炎的结果：11 例报告。
Respir Investig. 2020 Nov;58(6):430-434. doi: 10.1016/j.resinv.2020.08.001. Epub 2020 Aug 28.
9
An unusual case of bluish discoloration of the cornea after favipiravir therapy for COVID-19.一例新冠肺炎患者接受法匹拉韦治疗后角膜出现蓝色变色的罕见病例。
Indian J Ophthalmol. 2021 Dec;69(12):3778-3779. doi: 10.4103/ijo.IJO_1023_21.
10
Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.从一项法匹拉韦临床试验队列中分离的 SARS-CoV-2 的病毒学和基因组分析。
J Infect Chemother. 2021 Sep;27(9):1350-1356. doi: 10.1016/j.jiac.2021.06.010. Epub 2021 Jun 12.
引用本文的文献
1
Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database.法匹拉韦在新型冠状病毒肺炎中的应用：对世界卫生组织数据库中报告的疑似药物不良事件的分析
Infect Drug Resist. 2020 Dec 14;13:4427-4438. doi: 10.2147/IDR.S287934. eCollection 2020.
Zotero 插件